{{Infobox drug|verifiedrevid=461217017|image=Omaveloxolone structure.svg|width=250|alt=|caption=<!-- Names -->|pronounce=|tradename=Skyclarys|synonyms=RTA 408|IUPAC_name=N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-1 1-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b- octadecahydropicen-4a-yl)-2,2-difluoropropanamide

<!-- Clinical data -->|pregnancy_AU=<!-- A / B1 / B2 / B3 / C / D / X -->|pregnancy_AU_comment=|pregnancy_category=|routes_of_administration=[[By mouth]]|onset=|duration_of_action=|Drugs.com={{Drugs.com|monograph|omaveloxolone}}|MedlinePlus=<!-- Legal data -->|legal_AU=<!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->|legal_AU_comment=|legal_CA=<!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->|legal_CA_comment=|legal_DE=<!-- Anlage I, II, III or Unscheduled -->|legal_DE_comment=|legal_EU=|legal_EU_comment=|legal_NZ=<!-- Class A, B, C -->|legal_NZ_comment=|legal_UN=<!-- N I, II, III, IV / P I, II, III, IV -->|legal_UN_comment=|legal_UK=<!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->|legal_UK_comment=|legal_US=Rx-only|legal_US_comment=<ref name="Skyclarys FDA label">{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf |title=Archived copy |access-date=1 March 2023 |archive-date=1 March 2023 |archive-url=https://web.archive.org/web/20230301063942/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf |url-status=live }}</ref>|legal_status=<!-- For countries not listed above -->|DailyMedID=Omaveloxolone

<!-- Pharmacokinetic data -->|bioavailability=|protein_bound=|metabolism=|metabolites=|elimination_half-life=|excretion=<!-- Chemical and physical data -->|C=33|F=2|H=44|N=2|O=3|SMILES=O=C4C(\C#N)=C/[C@@]5(/C3=C/C(=O)[C@H]2[C@](CC[C@@]1(NC(=O)C(F)(F)C)CCC(C)(C)C[C@H]12)(C)[C@]3(C)CC[C@H]5C4(C)C)C|StdInChI=1S/C32H43NO4/c1-27(2)11-13-32(26(36)37-8)14-12-31(7)24(20(32)17-27)21(34)15-23-29(5)16-19(18-33)25(35)28(3,4)22(29)9-10-30(23,31)6/h15-16,20,22,24H,9-14,17H2,1-8H3/t20-,22-,24-,29-,30+,31+,32-/m0/s1|StdInChI_Ref={{stdinchicite|correct|chemspider}}|StdInChI_comment=|StdInChIKey=WPTTVJLTNAWYAO-KPOXMGGZSA-N|StdInChIKey_Ref={{stdinchicite|correct|chemspider}}|density=|density_notes=|melting_point=|melting_high=|melting_notes=|boiling_point=|boiling_notes=|solubility=|specific_rotation=}}

'''ଓମାଭେଲୋକ୍ସୋଲୋନ''', ([[ଇଂରାଜୀ ଭାଷା|ଇଂରାଜୀ ଭାଷାରେ]] '''Omaveloxolone'''), '''ସ୍କାଏକ୍ଲାରିସ୍''' ଏହାର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା  [[ଫ୍ରେଡରିକ ଆଟାକ୍ସିଆ]] ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।<ref name="PI2023">{{Cite web|title=DailyMed - SKYCLARYS- omaveloxolone capsule|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|website=dailymed.nlm.nih.gov|access-date=24 May 2023|archive-date=1 July 2023|archive-url=https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|url-status=live}}</ref> ଅତିକମରେ ୧୬ ବର୍ଷ ବୟସରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ।<ref name="PI2023" /> ଏହା ପାଟିରେ ଦିଆଯାଏ ।<ref name="PI2023">{{Cite web|title=DailyMed - SKYCLARYS- omaveloxolone capsule|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|website=dailymed.nlm.nih.gov|access-date=24 May 2023|archive-date=1 July 2023|archive-url=https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|url-status=live}}<cite class="citation web cs1" data-ve-ignore="true">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e "DailyMed - SKYCLARYS- omaveloxolone capsule"]. ''dailymed.nlm.nih.gov''. [https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e Archived] from the original on 1 July 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">24 May</span> 2023</span>.</cite></ref>

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା, ମୁଣ୍ଡବିନ୍ଧା, ଅଇ, ପେଟ ଯନ୍ତ୍ରଣା, ଥକାପଣ, ତରଳ ଝାଡ଼ା, ଏବଂ ମାଂସପେଶୀ ଯନ୍ତ୍ରଣା ହୋଇପାରେ ।<ref name="PI2023">{{Cite web|title=DailyMed - SKYCLARYS- omaveloxolone capsule|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|website=dailymed.nlm.nih.gov|access-date=24 May 2023|archive-date=1 July 2023|archive-url=https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|url-status=live}}<cite class="citation web cs1" data-ve-ignore="true">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e "DailyMed - SKYCLARYS- omaveloxolone capsule"]. ''dailymed.nlm.nih.gov''. [https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e Archived] from the original on 1 July 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">24 May</span> 2023</span>.</cite></ref> ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ [[ଇଡିମା]] କିମ୍ବା [[ଡିସଲିପିଡେମିଆ]] ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ ।<ref name="PI2023" /> ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।<ref name="PI2023" /> ଏହା କିପରି କାମ କରେ ତାହା ଅସ୍ପଷ୍ଟ; ଅବଶ୍ୟ ଏହା ପରମାଣୁ ଫ୍ୟାକ୍ଟର୍ ଏରିଥ୍ରଏଡ୍ ୨ ସମ୍ବନ୍ଧୀୟ ଫ୍ୟାକ୍ଟର୍ ୨ (Nrf2) ପଥକୁ ସକ୍ରିୟ କରୁଥିବା ପରି ଜଣାଯାଏ ।<ref name="PI2023" />

୨୦୨୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ପାଇଁ ଓମାଭେଲକ୍ସୋଲୋନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।<ref name="PI2023">{{Cite web|title=DailyMed - SKYCLARYS- omaveloxolone capsule|url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|website=dailymed.nlm.nih.gov|access-date=24 May 2023|archive-date=1 July 2023|archive-url=https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e|url-status=live}}<cite class="citation web cs1" data-ve-ignore="true">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e "DailyMed - SKYCLARYS- omaveloxolone capsule"]. ''dailymed.nlm.nih.gov''. [https://web.archive.org/web/20230701174203/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1a1100e-8318-1596-e053-2995a90a533e Archived] from the original on 1 July 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">24 May</span> 2023</span>.</cite></ref> ଏହାକୁ ୨୦୧୮ରେ ୟୁରୋପରେ ଅନାଥ ନାମକରଣ ଦିଆଯାଇଥିଲା ।<ref>{{Cite web|title=EU/3/18/2037|url=https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2037|website=European Medicines Agency|access-date=24 May 2023|language=en|date=17 September 2018|archive-date=12 March 2023|archive-url=https://web.archive.org/web/20230312112616/https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-18-2037|url-status=live}}</ref> ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୩ ସୁଦ୍ଧା ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୩୭୦,୦୦୦ ଡଲାର ଥିଲା ।<ref>{{Cite web|last=Buntz|first=Brian|title=Reata sets $370,000 annual cost for new nerve disorder drug|url=https://www.drugdiscoverytrends.com/reata-sets-370000-annual-cost-for-new-nerve-disorder-drug/|website=Drug Discovery and Development|access-date=24 May 2023|date=3 March 2023|archive-date=7 March 2023|archive-url=https://web.archive.org/web/20230307104622/https://www.drugdiscoverytrends.com/reata-sets-370000-annual-cost-for-new-nerve-disorder-drug/|url-status=live}}</ref>

== ଆଧାର ==
<references />
[[Category:ଚିକିତ୍ସା ବିଜ୍ଞାନ]]
[[Category:Translated from MDWiki]]
